April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up. In addition, acute safety data indicate there have been more than 300 major adverse cardiac events (MACE)-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.
ART’s bioresorbable stent is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months. According to ART CEO Machiel van der Leest, a three-month scaffolding period is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodeling.
“Our analysis of ART’s in vivo data confirms that stent dismantling is occurring at around three months, and the overall safety data look encouraging thus far,” said Renu Virmani, M.D., medical director/president, CVPath Institute, Gaithersburg, Md.
ART also reported that it has expanded its scientific advisory board with the appointment of interventional cardiologist Murat Tuzcu, M.D., Ph.D., vice chairman of the cardiology department at Sydell and Arnold Heart & Vascular Institute.
ART’s bioresorbable stent is not approved for investigational use or sale in the United States.
For more information: www.art-stent.com
November 18, 2024 
